Programme

Since the discovery of penicillin in 1928, antibiotics have saved hundreds of millions of lives – yet we take them for granted. Today, antibiotic-resistant infections kill up to 100,000 patients in American hospitals annually, 80,000 in China, and 25,000 in Europe and by 2050, infections that cannot be treated with antibiotics are projected to kill up to 10 million people globally every year – more than cancer. The fact that many bacteria have adapted to treatments is the result of the uncontrolled use of antibiotics ‘to treat the common cold’, as well as their use in the manufacture of cosmetics, farming products, and supposed ‘preventative measures’, while many pharmaceutical companies are unwilling to invest in developing new generations of antibiotics, citing low rates of return. What must be done to counter this new threat, and could viruses be instrumental in the battle against bacteria? Do new kinds of infection and antibiotic resistance pose a real risk to the average person? What should the state do to encourage the pharmaceutical industry to produce new generations of antibiotics? How can the use of antibiotics be brought under control? What further steps should be taken to prevent the spread of infectious diseases?

Moderator:
Alexey Bobrovsky , Head of the Economic Programme, Russia 24 TV Channel

Alexey Bobrovsky

Head of the Economic Programme, Russia 24 TV Channel

Alexey Bobrovsky was born on 15 August 1981. In 2002, he graduated from the Journalism Department of the Modern University for the Humanities in Moscow. He has worked as reporter and host on the TV-Centre Channel, Channel 1, Radio Station Business-FM. Since 2009, he has authored and presented the Kurs Dnya [Daily Rate of Exchange] on the Russia-24 TV Channel, Head of the Channel’s Service of Economic News. He is Editor-in-Chief of the Internet site Vestifinance.ru. Since 2016, he has been General Producer of Vestfinance Forum – a new interactive platform, featuring Andrey Klepach, Boris Titov, Alexander Novak, Ksenia Yudaeva and other authoritative economic experts.

Panellists
James Anderson , Chair, Association of the British Pharmaceutical Industry (ABPI) Antimicrobial resistance (AMR) Network; Head of Corporate Government Affairs, GSK (GlaxoSmithKline)
Steffen Brygger Lund , Vice President, Head of Nordic, Russia and Baltic Region, MSD
Nikolay Vlasov , Deputy Head, Federal Service for Veterinary and Phytosanitary Surveillance (Rosselkhoznadzor)
Lyalya Gabbasova , Member of Interagency Coordination Group on Antimicrobial Resistance, The United Nations Organizations
Vasily Ignatiev , General Director, R-Pharm JSC
Alexey Tutelyan , Member, Russian Academy of Sciences
Niels Hessmann , General Director, Bayer; General Representative, Russia and CIS, Bayer
Olivier Charmeil , Executive Vice President and General Manager, General Medicines and Emerging Markets, Sanofi

James Anderson

Chair, Association of the British Pharmaceutical Industry (ABPI) Antimicrobial resistance (AMR) Network; Head of Corporate Government Affairs, GSK (GlaxoSmithKline)

In his role as Head of Corporate Government Affairs, James leads engagement with the UK and other key Governments to deliver our strategic corporate agenda, spanning our pharmaceuticals, vaccines, consumer, R&D and Manufacturing businesses. He leads the creation of opportunities for partnering with the government and works to identify and mitigate risks. James also leads GSK advocacy on Antimicrobial Resistance. He helped launch the €650m Innovative Medicines Initiative AMR PPP, New Drugs for Bad Bugs, partnering with the EU Commission. He has worked extensively in the area, with the O’Neill Commission, WHO, Chatham House, Brookings and other Government programmes. He also Chairs the ABPI AMR Network. James also works to improve patient access to innovative medicines. He led GSK’s engagement in the EMA’s Adaptive Pathways pilot and the UK’s Accelerated Access Review. This builds on James’ previous experience, leading multiple partnerships with stakeholders including regulators, HTA agencies, patients and budget holders, to improve the way we develop and commercialise our products. James is the Vice-Chair of the Healthcare Taskforce to the OECD and Chair of the ABPI AMR Network. He has a MBA from Harvard Business School and a Molecular Biology degree from Cambridge.

Nikolay Vlasov

Deputy Head, Federal Service for Veterinary and Phytosanitary Surveillance (Rosselkhoznadzor)

Vlasov Nikolai Anatolyevich Deputy Head Date of birth: October 21, 1953 Education: higher Graduated from (when): K.I. Skryabin Moscow Veterinary Academy, 1978 Profession according to diploma, academic degree, title: biochemist, Doctor of Science (Biology), Professor Awards and honours: Award winner of the Lenin Komsomol and the RF Government in the field of science and technology; Certificate of Merit from the Federal Service for Veterinary and Phytosanitary Surveillance (2005); Certificate of Merit from the Ministry of Agriculture of the Russian Federation (2013); Certificate of Merit from the President of the Russian Federation (2015); Medal for “Contribution to Creation of the Eurasian Economic Union”, 2nd Class (2015). Delegate from the Russian Federation to the OIE (World Animal Health Organization), Member of the OIE Administrative Commission. Class ranking: Class 3 Active State Advisor of the Russian Federation Experience 1971 - 1973 - Laboratory Assistant at the M.V. Lomonosov Moscow State University, Moscow 1973 - 1978 - Student at the K.I. Skryabin Moscow Veterinary Academy, Moscow 1978 - 1992 - Senior Laboratory Assistant, Junior Laboratory Researcher, Senior Laboratory Researcher; Senior Department Researcher, Researcher in the "Biochemistry" sector of the All-Union Scientific Research Institute for Veterinary Virology and Microbiology of the Ministry of Agriculture of USSR, Pokrov, the Moscow region 1992 - 2000 - Head of Laboratory, Deputy Director for Research, Acting Head of the department, the All-Russian Scientific Research Institute for Veterinary Virology and Microbiology of the Russian Academy of Agriculture, Pokrov, the Moscow region 2000 - 2001 - Head of the Immunochemistry Department of the Municipal Scientific Center on Human and Animal Diseases Diagnostics and Prevention, Moscow 2001 - 2003 - Head of Laboratory of the Scientific Research Virology Institute named after D.I. Ivanovsky of the Russian Academy of Medical Sciences, Moscow 2003 - 2005 - Deputy Director for research of the Federal Governmental Institution "All-Russian State Center for Safety and Standardization of Human and Animal Drug Preparations and Feeds" of the Veterinary Department of the Russian Ministry of Agriculture, Moscow 2005 - 2006 - Deputy Head of the Administration for Veterinary Surveillance of the Federal Service for Veterinary and Phytosanitary Surveillance (Rosselkhoznadzor), Moscow 2006 - 2008 - Head of the Administration for Veterinary Surveillance of the Federal Service for Veterinary and Phytosanitary Surveillance (Rosselkhoznadzor), Moscow April 2, 2008 – present time - Deputy Head of the Federal Service for Veterinary and Phytosanitary Surveillance (Rosselkhoznadzor), Moscow

Vasily Ignatiev

General Director, R-Pharm JSC

Was born in 1968 in Moscow. In 1985 graduated from secondary school No.44 of Moscow with gold medal and entered the 1st medical faculty of the 1st Moscow Medical Institute (afterwards - Moscow Medical Academy) named after Sechenov. In 1987, having finished the 2nd course, was called to arms by the Military Forces. After demobilization in 1989 continued studying in MMA – first at the 1st medical faculty and from the 4th course at the Faculty of scientific and scientific-pedagogic personnel training, from which graduated with honors in 1993. While studying from June to October 1992, did traineeship in the University of Columbia (the city of New York, USA) within the framework of interuniversity program of students exchange. In 1993-1995 did postgraduate studies at the chair of clinical pharmacology of MMA named after Sechenov. In 1995-2002 occupied the positions of Product Manager, Marketing Manager, Marketing Director at the representative office of the international pharmaceutical company “Bristol-Myers Squibb”. In 2002-2006 worked in the position of Marketing and Sales Director in the representative office on the international pharmaceutical company “Astra-Zeneka”. Simultaneously from 2001 to 2007 pluralistically worked as research officer in the laboratory of historic and scientific researches of SPA “Medical Encyclopedia” of RAMS, in December of 2004 defended dissertation to seek the scientific degree of the medical sciences candidate. In 2006-2007 worked as Marketing and Sales Director in the Russian-Dutch tire holding of OJSC “Amtel-Fredestein”. Since 2008 work in the first rate Russian producer and distributor of pharmaceuticals “R-Pharm” as Chief Executive Officer. Married, six children.

Alexey Tutelyan

Member, Russian Academy of Sciences

Alexey Tutelyan was born in 1965 in Moscow. In 1988, he graduated from the Sanitary and Hygienic Faculty of I.M. Sechenov First Moscow State Medical University (later First Moscow State Medical University), after which he began his career as a research trainee at the Central Research Institute of Epidemiology of the Ministry of Health of the USSR (currently Federal Budget Institution of Science “Central Research Institute of Epidemiology” of the Federal Supervisory Service for Customers’ Rights and Public Welfare), where he has spent nearly 30 years, rising to the position of head of laboratory. In 1993, he defended his Candidate of Sciences thesis and then, in 2004, his doctoral thesis on topical issues of peptide regulation of immune response. Since 2011, he has been head of the Department of Molecular Immunology, Infectology and Pharmacotherapy of the Dmitry Rogachev National Research Centre of Paediatric Haematology, Oncology and Immunology. A. Tutelyan’s recent scientific interests have been focused on the study of molecular and cellular mechanisms for formation of infectious agent resistance to antibiotics and disinfectants. A.V. Tutelyan is a laureate of the Prize in the field of science and technology for 1999 awarded by the Government of the Russian Federation, author of over 150 scientific papers and four patents, he is a member of the expert council for preventive medicine of the Higher Attestation Commission of the Ministry of Education and Science of the Russian Federation, board member of the Russian Scientific Society of Immunologists, editorial board member of such magazines as “Allergology and Immunology”, “Epidemiology and Infectious Diseases. Current Issues” and “Questions of Virology”, expert of the Russian Academy of Sciences. He is married and has two children.

Niels Hessmann

General Director, Bayer; General Representative, Russia and CIS, Bayer

Niels Hessmann is the Managing Director of Bayer JSC and Senior Bayer Representative in Russia and CIS since March 1, 2015. Niels Hessmann was born in Belgium and studied applied economic sciences at the University of Antwerp, Belgium. He began his career as a Market Research Manager in Schering (now Bayer) in Belgium in 1992. In 1996, he headed the Marketing and Sales Department of Schering Romania and Moldova. In 1999, he became the Managing Director of Schering Kazakhstan and was responsible for the company development in Central Asia. In 2001, he was appointed the Managing Director of Schering Greece. In 2007, he headed Bayer Netherlands and was Bayer Healthcare Representative. During that period, Mr. Hessmann was also responsible for merging Bayer and Schering. From November 2011 to February 2015, he was the Managing Director and Country Division Head Bayer HealthCare in South-Korea.

Olivier Charmeil

Executive Vice President and General Manager, General Medicines and Emerging Markets, Sanofi

Olivier Charmeil is a graduate of HEC (Ecole des Hautes Etudes Commerciales) and of the Institut d’Etudes Politiques in Paris. He began his career in the Mergers & Acquisitions department of Bank of the European Union, from 1989 to 1994. He then joined Sanofi Pharma in 1994 as head of Business Development. Subsequently, he held various positions within the Group, including Head of the Sanofi Operations in France and Vice President Development, within the Sanofi-Synthélabo International Operations team, where he was responsible for China and support functions. He was appointed to Senior Vice President, Asia/Pacific & Japan, Pharmaceutical Operations, in February 2006. Olivier Charmeil became President & CEO, Sanofi Pasteur, on January 2011. He is a member of the Sanofi Executive Committee.